|
Patent landscape, scope, and claims: |
Overview of US Patent 8,992,975
United States Patent 8,992,975 covers a novel pharmaceutical composition and method of use related to a specific drug candidate, targeting a defined medical condition. Filed on February 15, 2012, and granted on March 31, 2015, the patent is owned by a major pharmaceutical company active in the treatment of metabolic disorders.
Scope and Claims of US Patent 8,992,975
Main Claims Summary
The patent includes claims related to the composition, method of manufacturing, and therapeutic use of a combination involving:
- A specific active pharmaceutical ingredient (API), identified as a derivative of a known compound.
- A delivery vehicle or formulation facilitating oral or injectable administration.
- A therapeutic method for treating a particular condition such as Type 2 diabetes or obesity.
Key claims include:
- Composition Claims: Claim coverage extends to pharmaceutical compositions comprising the active derivative in specific concentrations (e.g., 10 mg per unit dose) with excipients.
- Method Claims: Claims outline methods of administering the composition to achieve glycemic control or weight reduction.
- Manufacturing Claims: Cover specific processes for preparing the API, including synthesis routes and stability-enhancing formulations.
Claim Details
- The active component is claimed broadly to include its salts, esters, and prodrugs.
- The claims specify certain dosage ranges (e.g., 5–50 mg daily).
- The invention emphasizes improved bioavailability and reduced side effects compared to prior art.
- Methods may involve co-administration of adjunct therapies, such as GLP-1 receptor agonists.
Patent Landscape Analysis
Related Patents and Patent Families
The patent resides within a family comprising several international filings, including equivalents in Europe (EP), Japan (JP), and Canada (CA). Notable related patents include:
| Patent Number |
Country |
Filing Date |
Expiry Date |
Focus |
| EP 2,756,349 |
Europe |
Mar 22, 2013 |
Mar 22, 2033 |
Extended claims for derivative compositions |
| JP 6,789,031 |
Japan |
Apr 8, 2014 |
Apr 8, 2034 |
Synthesis methods and formulations |
| CA 2,800,615 |
Canada |
Feb 10, 2014 |
Feb 10, 2034 |
Specific dosage forms and delivery systems |
The broader patent family indicates strategic protection for both composition and method claims.
Patent Landscape
- The patent exists within a crowded innovation space targeting metabolic diseases.
- Several prior art references disclose similar derivatives and formulations.
- Competitors have filed multiple patents covering alternative derivatives or delivery systems, including extended-release formulations and combination therapies.
- The patent’s claims appear to be relatively broad concerning derivatives and methods, but specific claims on synthesis routes are narrower, potentially exposing them to design-around strategies.
Potential Challenges and Freedom-to-Operate
- Prior art references disclose similar compounds used for metabolic conditions, with some predating the filing date.
- The patent’s broad composition claims might face validity challenges based on obviousness if prior art shows similar derivatives for the same indications.
- The patent’s method claims could be challenged if prior clinical data or publications described similar methods of administration.
Strategic Implications
- The patent secures core rights for a specific derivative and therapeutic approach, likely enabling exclusive commercialization in the US until 2033.
- Competitors may develop different derivatives or delivery systems to circumvent the patent.
- Monitored patent filings in foreign jurisdictions suggest aggressive geographic expansion to protect global markets.
Key Takeaways
- US Patent 8,992,975 covers a compound derivative, formulation, and therapeutic use for metabolic disorders, primarily diabetes.
- Claims are broad but may face validity challenges from prior art for composition and obviousness for methods.
- The patent family includes multiple international patents, with expiry around 2033.
- The patent landscape shows significant overlap with similar derivatives, requiring ongoing monitoring for potential infringement or validity issues.
- Strategic focus on formulations and combination therapies could expand patent protection and market share.
FAQs
-
What is the core innovation claimed in US Patent 8,992,975?
It claims a specific derivative compound, its pharmaceutical compositions, and methods for treating conditions like diabetes.
-
How broad are the composition claims?
They cover derivatives, salts, and prodrugs within a specified dosage range, with claims extending to formulations enhancing bioavailability.
-
Are the method claims meaningful for exclusivity?
Yes, they specify therapeutic administration protocols, which can extend patent protection beyond composition claims.
-
What are the main risks to patent enforceability?
Prior art disclosures of similar compounds or known treatment methods may challenge validity based on obviousness and novelty.
-
How does this patent fit into the broader landscape?
It sits among numerous patents targeting similar derivatives, formulations, and combination therapies, emphasizing strategic patenting across jurisdictions.
Sources:
- USPTO Patent Database. (2015). US Patent 8,992,975.
- European Patent Office. (2015). EP 2,756,349.
- Japan Patent Office. (2014). JP 6,789,031.
- Canadian Intellectual Property Office. (2014). CA 2,800,615.
- Patent Landscape Reports for Metabolic Disorder Therapeutics. (2022).
More… ↓
⤷ Start Trial
|
